SPECIAL NOTICE
A -- Multi-disciplinary Approaches for the Diagnosis, Management, and Treatment of Sepsis - HHS-18-BARDA-RFI-00018
- Notice Date
- 4/17/2018
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- HHS-18-BARDA-RFI-00018
- Archive Date
- 5/15/2018
- Point of Contact
- Roshawn K. Simpson, , Francine L. Hemphill,
- E-Mail Address
-
roshawn.simpson@hhs.gov, Francine.Hemphill@hhs.gov
(roshawn.simpson@hhs.gov, Francine.Hemphill@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- RFI - Full Version This REQUEST FOR INFORMATION (RFI) is issued for informational and planning purposes only. This RFI is NOT a Solicitation; nor does it commit the Department of Health and Human Services (HHS) to issue a solicitation, make any award, or pay any costs associated with responding to this announcement. The information requested herein will be used within the HHS Biomedical Advanced Research and Development Authority (BARDA); and the Office of Acquisition Management, Contracts & Grants (AMCG) to facilitate program breakthrough capabilities as it relates to Solving Sepsis. Sepsis is among the leading causes of death in US hospitals and is often a complicating secondary confounder that can arise from primary infections due to CBRN insults, resulting from naturally occurring or intentional events. To fully address the U.S. ability to rapidly respond and recover from these threats, BARDA's mission is to develop a comprehensive portfolio of medical countermeasures, including non-pharmaceutical countermeasures, against a broad array of public health threats to ensure that their impact is minimized, aligning with the desire to reduce the incidence, mortality and morbidity of sepsis. Sepsis is among the most expensive conditions treated in US hospitals, representing approximately 6% of all hospitalizations, as well as a leading cause of hospital readmission. More than 1.7 million people in the U.S. are diagnosed with sepsis, with more than 250,000 dying each year. Despite many advances in care, fully effective treatment strategies for sepsis have remained elusive. There is an opportunity within this BARDA-defined critical area of "Solving Sepsis" to leverage considerable expertise and knowledge to develop new approaches to save lives, to reduce hospital burden and costs, and to improve the quality of life post-sepsis. BARDA is interested in understanding more about how multi-disciplinary, integrated technological approaches might be able to transform sepsis outcomes, which may include, but are not limited to, improving clinical management approaches; detection and diagnostic approaches and devices that could inform on sepsis from early symptoms to post-sepsis syndrome; data collection, analysis, integration and curation in both hospital and community wide settings; and advancing products and capabilities that better inform sepsis natural history and pathophysiology. As sepsis is not just limited to hospital infections, information on approaches that recognize community-wide solutions, are also of interest. BARDA is seeking information regarding interventions that could generate a truly comprehensive strategy to mitigate sepsis and save lives. The goal of this RFI is to solicit relevant information on the current and planned capabilities and intent of industrial and academic investigators to address sepsis. Various information, data, videos and materials may be submitted to support interest and capability to develop novel approaches to the diagnosis, management and treatment of sepsis. Of particular interest are existing or planned databases for sepsis clinical data; enabling rapid and reliable early indicators of sepsis and its severity; and, techniques and devices that improve outcomes by modifying disease management; and therapeutic agents that positively impact survival and substantively reduce post-sepsis morbidity. While we recognize that antibiotics often play a critical role in treatment of many sepsis cases, amidst the growing global concern raised by rising rates of anti-microbial resistance, this RFI is not seeking information on novel antibiotics in development. BARDA has established programs, such as CARB-X, http://carb-x.org/, a public-private partnership, focused on bringing effective new antimicrobial therapeutics and diagnostics to the market. Therefore this RFI, only seeks input on approaches that are specific to sepsis in terms of a novel comprehensive strategy that would realize truly ‘game changing' breakthroughs.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/HHS-18-BARDA-RFI-00018/listing.html)
- Record
- SN04891952-W 20180419/180417230758-854f9833bde05babb017caf5434a6cc8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |